CLL – The impact of using ibrutinib as front-line treatment
This is the first study to use real-world evidence to describe and compare the time to the next treatment outcomes between ibrutinib and acalabrutinib in patients with treatment-naïve CLL. In this MEDtalk Ryan Jacobs, Atrium Health Levine Cancer Institute, presents the data.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
